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Abstract
There is currently a pandemic caused by the novelBackground: 
coronavirus SARS-CoV-2. The intensity and duration of this first wave in the
UK may be dependent on whether SARS-CoV-2 transmits more effectively
in the winter than the summer and the UK Government response is partially
built upon the assumption that those infected will develop immunity to
reinfection in the short term. In this paper we examine evidence for
seasonality and immunity to laboratory-confirmed seasonal coronavirus
(HCoV) from a prospective cohort study in England.
In this analysis of the Flu Watch cohort, we examine seasonalMethods: 
trends for PCR-confirmed coronavirus infections (HCoV-NL63,
HCoV-OC43, and HCoV-229E) in all participants during winter seasons
(2006-2007, 2007-2008, 2008-2009) and during the first wave of the 2009
H1N1 influenza pandemic (May-Sep 2009). We also included data from the
pandemic and ‘post-pandemic’ winter seasons (2009-2010 and 2010-2011)
to identify individuals with two confirmed HCoV infections and examine
evidence for immunity against homologous reinfection.
We tested 1,104 swabs taken during respiratory illness andResults: 
detected HCoV in 199 during the first four seasons. The rate of confirmed
HCoV infection across all seasons was 390 (95% CI 338-448) per 100,000
person-weeks; highest in the Nov-Mar 2008/9 season at 674 (95%CI
537-835). The highest rate was in February at 759 (95% CI 580-975). Data
collected during May-Sep 2009 showed there was small amounts of
ongoing transmission, with four cases detected during this period. Eight
participants had two confirmed infections, of which none had the same
strain twice.
 Our results provide evidence that HCoV infection in EnglandConclusion:
1* 1,2* 1,2 3
4 2 1,5
1
2
3
4
5
*
 Reviewer Status AWAITING PEER REVIEW
 30 Mar 2020,  :52 (First published: 5
)https://doi.org/10.12688/wellcomeopenres.15812.1
 30 Mar 2020,  :52 (Latest published: 5
)https://doi.org/10.12688/wellcomeopenres.15812.1
v1
Page 1 of 8
Wellcome Open Research 2020, 5:52 Last updated: 09 APR 2020
  Our results provide evidence that HCoV infection in EnglandConclusion:
is most intense in winter, but that there is a small amount of ongoing
transmission during summer periods. We found some evidence of immunity
against homologous reinfection.
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Background
We write this paper during a pandemic caused by the novel 
coronavirus SARS-CoV-2. As of 22nd March 2020, there were 
294,110 confirmed cases and 12,944 deaths reported from 
186 countries, areas or territories with cases1. In the UK, 
5,683 confirmed cases have been reported and 281 patients 
who tested positive for SARS-CoV-2 have died2. The UK 
Government aims to reduce the peak of the first wave through 
social distancing measures including asking people to stay at 
home and only go outside for food, health reasons or work where 
this absolutely cannot be done from home. This aims to minimise 
burden on hospitals during the first wave of the pandemic. 
In addition to social distancing measures, the intensity and 
duration of this first wave will be dependent on whether 
SARS-CoV-2 transmits more effectively in the winter than the 
summer. Mathematical models used to predict the transmis-
sion and impact of COVID-19 in the UK assume that the virus 
will produce an immune response that prevents reinfection in the 
short term3.
Existing studies from outside the UK suggest that incidence 
of human coronaviruses in temperate climates is usually highest 
during winter, but spring and summer peaks and year-round cir-
culation at varying levels have also been found4–9. There is mini-
mal evidence regarding immunity and risk of repeat infection, but 
reinfection with common strains (HCoV OC43/229E) has been 
documented10,11 and reinfection with SARS-CoV appears to be 
theoretically plausible as it has been shown that antibody titres 
appear to decline over time, with estimates for duration of 
protection up to three years12.
Flu Watch is a cohort study measuring the community incidence 
and transmission of several respiratory viruses in England13. The 
study has the advantage of identifying mild cases of respi-
ratory infection regardless of whether they lead to medical 
attendance and can therefore measure community incidence 
of infection over time and reinfection regardless of severity. 
We aimed to describe the community incidence and seasonal 
patterns of seasonal coronavirus strains, assess the frequency of 
reinfection with homologous and heterogeneous strains, and 
among participants with two confirmed HCoV infections, 
examine how likely we were to observe the number of homolo-
gous reinfections if participants had no immunity.
Methods
Study design and procedure
This study is based on analysis of data collected as part of the 
Flu Watch study, a prospective community cohort study of 
the transmission and burden of acute respiratory illness in UK 
households. The full study design and methodology has 
been described previously13. Follow-up occurred across three 
consecutive winter seasons (Nov-Mar 2006–2007, 2007–2008, 
2008–2009), the summer and winter waves of the 2009 H1N1 
influenza pandemic (May-Sep 2009, Oct-Feb 2009–2010) and 
‘post-pandemic’ winter season (Nov-Mar 2010–2011).
Demographic data were collected at the start of each season and 
in this analysis we used age, sex, geographical region, quintile of 
Index of Multiple Deprivation 2007 (a composite measure of the 
socioeconomic status of small neighbourhoods)14. Throughout 
the season, participants were contacted weekly (via telephone or 
emailed online surveys) and asked to provide reports stat-
ing whether anyone in the household had experienced symp-
toms of acute respiratory illness. During all days of illness, 
participants were asked to report their symptoms and whether 
they took any time off work or study. In addition, we requested 
that all participants experiencing respiratory symptoms provide 
self-administered nasal swabs on the second day of illness. 
In the first season, participants received swabs via the post 
only when they reported illness (so swabs are likely to have 
arrived later than day two of illness) and swabbing began in late 
December 2006. In all subsequent seasons, participants received 
swabs at the beginning of follow up and we requested swabs for all 
illnesses regardless of when they occurred during follow up. Full 
details of sample handling and testing are provided elsewhere13,15. 
All swabs were tested for HCoV during the first four seasons, but 
only selected swabs were tested for HCoV in the pandemic and 
post-pandemic winter seasons. Table 1 summarises respiratory 
virus PCR testing across Flu Watch seasons.
We have published the full dataset used in this study (see 
underlying data).
Participants
Participants were randomly selected from participating 
general practice lists in England. All household members 
of each participant were invited. Households were recruited 
before each winter season. From 2008–2009, households that 
had previously participated were also re-invited to the study. 
Participants were eligible if all household members agreed to 
participate for the full season and adult household members 
(aged 16 years and older) agreed to provide blood samples for 
influenza-related research. Participants were not eligible if their 
household was larger than 6 people, if any household member 
suffered from terminal or severe illness or incapacity, or had 
heavy concurrent involvement in other research.
Outcomes
The primary outcome of interest in this study was PCR-
confirmed coronavirus infection in participants. Three 
coronavirus strains were tested: HCoV-NL63, HCoV-OC43, and 
HCoV-229E.
Statistical analysis
We calculated the rate of PCR-confirmed coronavirus infection 
per 100,000 person-weeks. Follow-up began at the start of 
each season and ended at the earliest of the final report of 
symptoms or the end of the season. We stratified rates by 
participants’ age, sex, geographical region, quintile of Index of 
Multiple Deprivation 200714, and study season. We used a 
mixed poisson model to estimate rate ratios for confirmed 
HCoV. The dependent variable was the count of HCoV infec-
tions per season, the independent variables were participant 
characteristics at the start of each season plus an offset for 
the duration of follow-up, and the model was clustered by 
individual and household. For these descriptive analyses, we 
excluded the pandemic and post-pandemic winter seasons 
(2009–2010 and 2010–2011) as not all samples were tested for 
HCoV during these two seasons.
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Table 1. Respiratory virus PCR* testing on nasal swabs across Flu Watch seasons.
Nov 2006 
– Mar 2007
Nov 2007 
– Mar 2008
Nov 2008 
– Mar 2009
May 2009 
– Sep 2009
Oct 2009 
– Feb 2010
Nov 2010 
– Mar 2011
HCoV** ✓ ✓ ✓ ✓ partial partial
Influenza A (H1N1) ✓ ✓ ✓ ✓ ✓ ✓
Influenza A (H3N2) ✓ ✓ ✓ ✓ ✓ ✓
Influenza A 
(H1N1pdm09) n/a n/a n/a ✓ ✓ ✓
Influenza B ✓ ✓ ✓ ✓ ✓ ✓
RSV*** ✓ ✓ ✓ ✓ ✓ ✓
hMPV**** ✓ ✓ ✓ ✓ ✓ ✓
Adenovirus ✓ ✓ ✓ ✓ partial partal
Parainfluenza virus ✓ ✓ ✓ ✓ partial partial
Rhinovirus ✓ ✓ ✓ ✓ partial partial
*Polymerase chain reaction
**Human Coronavirus
***Respiratory syncytial virus
****Human Metapneumovirus
We used HCoV strains in participants with repeat infections 
to test the evidence for homologous immunity after infection. 
We assumed that with no immunity the distribution of strains 
among participants with a second infection would be the 
same as in the entire cohort (i.e. the first infection would 
have no bearing on the second one) and then simulated 
100,000 scenarios of the strains causing the second infection 
(HCoV-NL63, HCoV-OC43 or HCoV-229E). We interpreted the 
proportion of simulations with as many or fewer homologous 
reinfections than in the observed data as evidence of immunity. 
Figure S1 (extended data16) shows the first ten simulations and 
provides further detail of this method. For this analysis, we 
included data from the final two winter seasons (2009–2010 and 
2010–2011).
We also estimated the percent of illnesses that were swabbed 
and tested for the relevant seasonal panel of viruses (see 
Table S1 extended data16) as well as for HCoV by season to aid 
interpretation of results. 
Analysis was conducted using R version 3.6.2.
Ethics and consent
The ethical protocol for Flu Watch was approved by the 
Oxford MultiCentre Research Ethics Committee. (06/Q1604/103). 
Participants gave written informed consent (proxy consent for 
children).
Results
Approximately 10% of invited households agreed to participate 
in Flu Watch. Compared to the national population, the study 
population underrepresented young adults; people living in 
socially deprived areas, north England, west Midlands, and 
London; and people of non-white ethnic origin. We included 
51,002 person-weeks of follow-up and 2,907 person-seasons in the 
first four seasons. 
A total of 1,104 swabbed illnesses were tested for HCoV and 
199 cases were confirmed in the first four seasons. This total 
excludes six HCoV positive swabs (three in winter 2008–2009 
and three in winter 2009–2010) as they were submitted 
without a participant ID. The percent of illnesses that were 
swabbed varied by season with lower adherence during Nov 
2007 – Mar 2008 and May 2009 – Sept 2010 (61.5% and 
57.0% respectively) and better adherence in the other seasons 
ranging from 83.6%–96.9% (see extended data 2 table S1). 
In the last two seasons when there was only partial testing 
(Oct 2009 – Feb 2010 and Nov 2010 – Mar 2011) the per-
cent of illnesses swabbed and tested for HCoV was 14.0% and 
24.5% respectively, which is why we did not report HCoV rates 
for these seasons. 
We calculated an HCoV incidence rate of 390 per 100,000 
person-weeks (95% CI 338–448) across the first four seasons. 
The maximum rate of HCoV according to age was bimodal, 
peaking at ages 0–4 and ages 16–44. Rates were similar in 
males and females, by geographical region, and by level of 
deprivation. Rates and rate ratios for participant characteristics are 
shown in Table 2.
Rates were higher in winter seasons than in the summer season 
of May-Sep 2009, during which four cases of HCoV were 
detected. Combining data across the first four seasons showed 
rates were highest in the month of February (759; 95%CI 
580–975). Considering all respiratory viruses tested for, HCoV 
and Influenza both peaked in winter and then declined, whereas 
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Table 2. Baseline characteristics of study participants and HCoV PCR+ illness rates across the first four seasons (Nov-Mar 2006/7; 
Nov-Mar 2007/8; Nov-Mar 2008/9; May-Sep 2009).
Variable Level Individuals Person- 
Seasons
Person-
weeks
HCoV* 
PCR**+
HCoV 
PCR**+/100,000 
person-weeks 
(95% CI)
Rate ratio 
(unadjusted)
Rate ratio 
(adjusted)
Total 1,847 (100.0%) 2,907 51,002 199 390 (338-448)
Age group 0-4 111 (5.8%) 153 2,530 18 711 (422-1,124) 1 1
5-15 272 (14.3%) 405 7,021 27 385 (253-560) 0.51 (0.27-0.96) 0.50 (0.26-0.94)
16-44 537 (28.2%) 773 13,180 60 455 (347-586) 0.69 (0.39-1.20) 0.67 (0.38-1.17)
45-64 650 (34.1%) 1,035 18,487 65 352 (271-448) 0.53 (0.30-0.94) 0.55 (0.31-0.97)
65+ 337 (17.7%) 541 9,784 29 296 (199-426) 0.45 (0.23-0.86) 0.48 (0.25-0.91)
Sex Female 973 (52.7%) 1,543 26,986 105 389 (318-471) 1 1
Male 874 (47.3%) 1,364 24,016 94 391 (316-479) 1.01 (0.76-1.34) 1.01 (0.76-1.34)
Region East & East Midlands 318 (17.1%) 484 8,573 29 338 (227-486) 1 1
London 116 (6.2%) 159 2,564 11 429 (214-768) 1.44 (0.65-3.18) 1.24 (0.56-2.76)
North 273 (14.7%) 394 6,898 26 377 (246-552) 1.16 (0.63-2.14) 1.14 (0.61-2.12)
South East 297 (16.0%) 479 8,179 22 269 (169-407) 0.85 (0.45-1.58) 0.83 (0.44-1.57)
South West 698 (37.5%) 1,154 20,545 92 448 (361-549) 1.33 (0.82-2.17) 1.49 (0.91-2.44)
West Midlands 159 (8.5%) 237 4,243 19 448 (270-699) 1.42 (0.73-2.78) 1.32 (0.67-2.59)
IMD*** 2007 1 - most deprived 99 (4.6%) 136 2,453 14 571 (312-958) 1 1
2 284 (13.3%) 366 6,499 30 462 (311-659) 0.83 (0.38-1.81) 0.89 (0.41-1.95)
3 534 (25.0%) 804 14,229 62 436 (334-559) 0.76 (0.37-1.55) 0.74 (0.36-1.53)
4 513 (24.1%) 730 12,924 46 356 (261-475) 0.64 (0.31-1.33) 0.69 (0.33-1.44)
5 - least deprived 409 (19.2%) 578 9,971 44 441 (321-592) 0.83 (0.39-1.73) 1.03 (0.49-2.16)
Missing 293 (13.7%) 293 4,926 3 61 (13-178) 0.09 (0.02-0.33) 1.76 (0.30-10.21)
Season Nov-Mar 2006/7 602 (20.7%) 602 10,751 42 391 (282-528) 1 1
Nov-Mar 2007/8 779 (26.8%) 779 14,183 70 494 (385-624) 1.30 (0.85-1.99) 1.31 (0.85-2.02)
Nov-Mar 2008/9 729 (25.1%) 729 12,315 83 674 (537-835) 1.68 (1.12-2.53) 1.68 (1.12-2.53)
May-Sep 2009 797 (27.4%) 797 13,753 4 29 (8-74) 0.07 (0.03-0.21) 0.05 (0.01-0.21)
Month Jan 1,737 (15.4%) 2,023 8,534 61 715 (547-918)
Feb 1,740 (15.5%) 2,033 8,040 61 759 (580-975)
Mar 1,722 (15.3%) 2,007 9,241 13 141 (75-241)
May 681 (6.0%) 681 2,643 0 0 (0-140)
Jun 679 (6.0%) 679 3,346 3 90 (18-262)
Jul 649 (5.8%) 649 2,514 0 0 (0-147)
Aug 602 (5.3%) 602 2,941 0 0 (0-125)
Sep 670 (6.0%) 670 2,309 1 43 (1-241)
Nov 1,114 (9.9%) 1,280 3,050 4 131 (36-336)
Dec 1,666 (14.8%) 1,942 8,384 56 668 (505-867)
* Human Coronavirus
** Polymerase chain reaction
*** Index of Multiple Deprivation
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hMPV, adenovirus, RSV, and rhinovirus showed no obvious 
winter peak, though this may relate to the small number of cases 
we detected (Figure 1).
Of 216 participants with a first confirmed HCoV infection 
during any of the six seasons, eight had a second confirmed 
HCoV infection (all eight were from different households). These 
participants are shown in Table 3. None of the eight participants 
had the same strain twice. No participants had a third confirmed 
HCoV infection. Based on simulations assuming no immunity, 
the probability of zero homologous reinfections in these eight 
participants was 3.48%, suggesting some evidence for immunity 
(Figure S2 extended data16).
Discussion
Our study shows that HCoV appears to follow a seasonal 
pattern in England, with peaks occurring during winter seasons 
and broadly at the same time as Influenza. We collected data 
during one summer season that coincided with the start of the 
2009 H1N1 Influenza pandemic, and during this period we 
found a small amount of ongoing HCoV transmission. Our 
results provide some evidence of immunity against homologous 
reinfection.
Our results support existing evidence for seasonality of HCoV 
in England with reduced transmission during summer months. 
To our knowledge, this is the first published study of HCoV 
Figure 1. Weekly rates of PCR-confirmed viral respiratory diseases. PCR= Polymerase chain reaction, RSV = Respiratory syncytial virus.
Table 3. Participants with repeated confirmed coronavirus infections.
First confirmed 
infection
Second confirmed 
infection
Weeks between 
infectionsNumber
Week 
commencing Strain
Week 
commencing Strain
1 04-Feb-08 229E 19-Jan-09 NL63 50
2 24-Nov-08 NL63 21-Dec-09 229E 56
3 01-Dec-08 OC43 16-Mar-09 229E 15
4 15-Dec-08 OC43 02-Feb-09 NL63 7
5 22-Dec-08 NL63 09-Feb-09 OC43 7
6 22-Dec-08 OC43 09-Feb-09 NL63 7
7 12-Jan-09 NL63 22-Jun-09 229E 23
8 16-Feb-09 229E 21-Dec-09 OC43 44
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seasonality in England and the first to show continued transmis-
sion during summer months. A 2010 review9 of HCoV-NL63 
found that it broadly followed a winter seasonal distribution in 
temperate climates (Belgium, Canada, France, Germany, Italy, 
Switzerland) with greater variation in tropical climates with 
China (Hong Kong) showing a spring and summer distribu-
tion (one study) and peaks in autumn in Thailand and October in 
Taiwan. Two further studies have been published since this 
review. The first was a community surveillance study in Utah, 
USA, which showed a broadly winter seasonal pattern8. Another 
study of swab specimens from adults and children with fever 
and acute upper respiratory infection symptoms in Guangzhou, 
China, found transmission throughout the year with a peak in 
February7.
Limited data exist on the immunising effect of previous 
infection with HCoV. Our data provide additional support for 
the immunising effect of infection in the short to medium term, 
but reinfection has been documented elsewhere. Our results 
should be interpreted with caution due to our sample size and 
the fact that we have not accounted for seasonal variations in 
strains, but it should also considered in the context of existing 
literature on immunity to HCoV, including community surveil-
lance and experimental reinfection challenge studies. In a 1971 
study of 937 medical students, reinfection with HCoV-229E 
was detected and infection with other respiratory viruses did 
not stimulate significant complement factor or neutralising 
antibody titre rises against HCoV-229E10. A combined paedi-
atric hospital inpatient and household community surveillance 
study conducted in Kenya found second infections with HCoV-
NL63 (20.9%), HCoV-OC43 (5.7%), and HCoV-229E (4.0%) 
over the six years of the study. This study provided evidence to 
rule out genotype switching as a possible mechanism for 
reinfection. Two studies have also demonstrated experimental 
HCoV reinfection in humans17,18. At the time of writing, one 
animal study has been conducted to examine the possibility of 
SARS-CoV-2 reinfection19. In this study, four 3- to 5-year old 
rhesus macaques were inoculated with SARS-CoV-2 and after 
the disappearance of symptoms, two were rechallenged and no 
viral load was detected. This study is important as it provides 
the only data we currently have on SARS-CoV-2, but it should 
also be interpreted with caution due to the fact that it is a primate 
study with a small sample size.
There are several additional limitations to our analysis and 
data. Our PCR data are reliant on participants sampling when 
symptomatic, which means that we will have not detected 
asymptomatic infection leading to underascertainment of such 
cases and as a result our estimates of rates will underestimate 
the true community burden. It is likely that we also received 
fewer samples from those who were minimally symptomatic. 
Our results therefore represent minimal burden estimates and 
we were unable to examine this further as we have no paired 
serological data on HCoV, although stored residual sera are 
available for this cohort and could be examined in future. 
Additionally, we were not able to calculate rates of confirmed 
HCoV infection in the final two winter seasons because not 
all swabs were tested for HCoV. Participants were advised to 
collect samples on day two of symptoms as Flu Watch was 
primarily set up to examine Influenza and we are uncertain 
whether or not this is the optimum day for sampling those 
with HCoV. We only have one year of data collection during 
summer, during which time adherence to swabbing was lower 
than winter periods. Our ability to confidently estimate the 
levels of transmission during the summer is limited as a result 
of this, as is our description of seasonality, although as we 
have discussed earlier, these results are consistent with the 
wider literature for HCoV transmission in temperate climates. 
The generalisability of our results to SARS-CoV-2 has uncer-
tainties, but given the lack of data on this novel virus, we believe 
that these data can help inform the public health response. At this 
stage in the pandemic, it appears to be the case that the clinical 
features of mild cases of SARS-CoV-2 are similar to NL63, 
OC43 and 229E, but the likelihood of developing severe 
disease or dying is much higher although considerably less than 
in SARS-CoV and MERS-CoV20,21.
In summary, our data provide additional support for a winter 
seasonal pattern of HCoV in the UK and that infection has an 
immunising effect against subsequent reinfection in the short 
to medium term. For COVID-19, in the context of intensive 
control measures it may prove difficult to assess the extent to 
which virus transmission is impeded by summer conditions. 
Comparing transmission the patterns in northern and southern 
hemispheres (where seasons are reversed) will be of help in 
providing early data on this. We also need further research to 
assess the strength and duration of immune protection following 
COVID-19 exposure. Whilst our results can help inform the 
response and modelling to SARS-CoV-2 in the UK, there 
are important research questions that need answering from 
community surveillance studies that are relevant to the policy 
and public health response. We urgently need to know the true 
extent of community transmission, including estimates of the 
asymptomatic fraction of SARS-CoV-2, the symptomatology 
in community cases and case hospitalisation rates in confirmed 
cases and how this varies over time and season. Additionally, we 
need to know what the duration of viral shedding is and 
whether there is evidence for repeat infection of SARS-CoV-2 in 
humans.
Data availability
Underlying data
UCL Discovery: Dataset: Seasonality and immunity to 
laboratory-confirmed seasonal coronaviruses (HCoV-NL63, 
HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort 
study. https://doi.org/10.14324/000.ds.1009390916
This project contains the following underlying data:
-   Aldridge_cov_seasonality_immunity_public_data_23_
march_2020.csv (Flu Watch HCoV data)
Extended data
UCL Discovery: Dataset: Seasonality and immunity to 
laboratory-confirmed seasonal coronaviruses (HCoV-NL63, 
HCoV-OC43, and HCoV-229E): results from the Flu Watch 
cohort study. https://doi.org/10.14324/000.ds.1009390916
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This project contains the following extended data:
-     Aldridge_cov_seasonality_immunity_public_code_revised.
R (Analysis replication code)
-     Aldridge_Extended data 1.pdf (Pdf file containing 
Table S1 and Figure S1 and S2)
o     Table S1. Illnesses swabbed and tested for HCoV by 
season
o     Figure S1: First ten simulations to evaluate 
evidence of homologous immunity
o     Figure S2: Probability of number of homologous 
reinfections in 8 participants, with the assumption of 
no immunity
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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